Open AccessInduction of sustained patency after clot-selective coronary thrombolysis with Hybrid-B, a genetically engineered plasminogen activator with a prolonged biological half-life.
Author(s) -
Carla J. Weinheimer,
Harold L. James,
Narender K. Kalyan,
J Wilhelm,
S G Lee,
P.P. Hung,
Burton E. Sobel,
Steven R. Bergmann
Publication year - 1991
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/01.cir.83.4.1429
Subject(s) - medicine , thrombolysis , plasminogen activator , bolus (digestion) , tissue plasminogen activator , coronary occlusion , fibrinolysis , fibrinogen , cardiology , myocardial infarction , anesthesia
Despite the utility of tissue-type plasminogen activator (t-PA) in eliciting coronary thrombolysis clinically, early reocclusion remains a problem, occurring despite anticoagulation in 5-30% of patients with initially successful recanalization. This study evaluated the utility of Hybrid-B, a molecular variant of t-PA with a prolonged half-life in the circulation, in eliciting coronary thrombolysis and maintaining patency in the presence of a continuing thrombogenic stimulus.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom